DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 9,446,134 B2 Maggio (45) Date of Patent: *Sep

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 9,446,134 B2 Maggio (45) Date of Patent: *Sep USOO9446.134B2 (12) United States Patent (10) Patent No.: US 9,446,134 B2 Maggio (45) Date of Patent: *Sep. 20, 2016 (54) STABILIZING ALKYLGLYCOSIDE 5, 198420 A 3, 1993 Donahoe et al. COMPOSITIONS AND METHODS THEREOF 5,369,095 A 11/1994 Kee 5,556,757 A 9/1996 Alstyne et al. (71) Applicant: Aegis Therapeutics, LLC, San Diego, 5,556,940 A 9, 1996 Willick et al. 5,661,130 A 8, 1997 Meezan CA (US) 6,524,557 B1 2/2003 Backstrom et al. (72) Inventor: Edward T. Maggio, San Diego, CA 6,551,578 B2 4/2003 Adjei et al. (US) 7,425,542 B2 9/2008 Maggio 7.998,927 B2 8/2011 Maggio (73) Assignee: Aegis Therapeutics, LLC, San Diego, 8,133,863 B2 * 3/2012 Maggio ........................ 514,111 CA (US) 8,226,949 B2 7/2012 Maggio 2002/0110524 A1 8, 2002 Cowan et al. (*) Notice: Subject to any disclaimer, the term of this 2004/0209814 A1 10/2004 Nauck patent is extended or adjusted under 35 2005/0215475 A1 9/2005 Ong et al. U.S.C. 154(b) by 0 days. 2005/0276843 A1 12/2005 Quay et al. 2006, 0046962 A1 3/2006 Meezan et al. This patent is Subject to a terminal dis 2006, OO74025 A1 4/2006 Quay et al. claimer. 2006/00846.04 A1 4/2006 Kitaura et al. 2006,0183674 A1 8, 2006 Brand (21) Appl. No.: 14/494,990 2007/011 1938 A1 5/2007 Pert 2008. O194461 A1 8/2008 Maggio (22) Filed: Sep. 24, 2014 2008/0268032 A1 10/2008 Maggio (65) Prior Publication Data 2009/0047347 A1 2/2009 Maggio 2009. O156478 A1 6/2009 Lau et al. US 2015/0216980 A1 Aug. 6, 2015 2009/0326193 A1 12/2009 Maggio Related U.S. Application Data FOREIGN PATENT DOCUMENTS (63) Continuation of application No. 13/544,851, filed on WO WO 2006/025882 A3 3, 2006 Jul. 9, 2012, now Pat. No. 8,846,044, which is a WO WO 2006/051110 A3 5, 2006 continuation of application No. 12/618,558, filed on Nov. 13, 2009, now Pat. No. 8,226,949, which is a continuation-in-part of application No. 12/119,378, OTHER PUBLICATIONS filed on May 12, 2008, now Pat. No. 7.998,927, which Brown and Schonbrunn, "Affinity Purification of a Somatostatin is a continuation-in-part of application No. Receptor-G-Protein Complex demonstrates Specificity in Receptor 12/050,038, filed on Mar. 17, 2008, now Pat. No. G-Protein Coupling.” J. Biol. Chem. (1993), 268(9):6668-6676. The 8,084,022, which is a continuation-in-part of American Society for Biochemistry and Molecular Biology, Inc. application No. 11/474,055, filed on Jun. 23, 2006, Hovgaard et al., "Stabilization of Insulin by Alkylmaltosides. A. now Pat. No. 7,425,542. Spectroscopic Evaluation.” Int. J. Pharm. (1996), 132: 107-113, (51) Int. Cl. Elsevier Science B.V. A6 IK 38/08 (2006.01) Hovgaard et al., "Stabilization of Insulin by Alkylmaltosides. B. A6 IK 47/26 (2006.01) Oral Absorption in vivo in Rats.” Int. J. Pharm. (1996), 132:115 A6 IK 9/00 (2006.01) 121, Elsevier Science B.V. A 6LX 9/27 (2006.01) Mitrano and Newton, “Factors Affectina Insulin Adherence to Type A 6LX 9/19 (2006.01) I Glass Bottles”, Am. J. Hosp. Pharm. (1982), 39(9): 1491-1495. Van Der Lubben et al., “Chitosan and its Derivatives in Mucosal A6 IK3I/70 (2006.01) Drug and Vaccine Delivery.” Eur.J. Pharm, Sci. (2001) 14:201-207, A6 IK 45/06 (2006.01) Elsevier. A6 IK 47/10 (2006.01) Ahsan et al., “Mutual inhibition of the insulin absorption-enhancing A6 IK 47/8 (2006.01) properties of dodecylmaitoside and dimethyl-beta-cyclodextrin fol A6 IK 47/36 (2006.01) lowing nasal administration’. Pharm Res., 18(5):608-14 (2001). (52) U.S. Cl. (Continued) CPC ............. A61K 47/26 (2013.01); A61K 9/0043 (2013.01); A61K 9/127 (2013.01); A61K 9/19 (2013.01); A61 K3I/70 (2013.01); A61K 38/08 Primary Examiner — Jeffrey E. Russel (2013.01); A61K 45/06 (2013.01); A61K 47/10 (2013.01); A61K 47/186 (2013.01); A61 K (74) Attorney, Agent, or Firm — DLA Piper LLP (US) 47/36 (2013.01) (58) Field of Classification Search (57) ABSTRACT None See application file for complete search history. The present invention relates to alkylglycoside-containing compositions and methods for increasing the stability, (56) References Cited reducing the aggregation and immunogenicity, increasing the biological activity, and reducing or preventing fibrillar U.S. PATENT DOCUMENTS formation of a peptide, polypeptide, or variant thereof, for 4,130,709 A 12/1978 Nagarajan example octreotide or variant thereof. 4,440,675 A 4, 1984 Braude 4476,116 A 10, 1984 Anik 5, 122,187 A 6, 1992 Schwarz et al. 25 Claims, 15 Drawing Sheets US 9,446,134 B2 Page 2 (56) References Cited European Search Report (ESR) from application No. EP 1079 2685., completed Jul. 8, 2013. OTHER PUBLICATIONS Tachibana, Hiroshi et al.: “Differentiation of Entamoeba histolytica Vanaken et al., “Alkyl glycoside detergents: synthesis and applica- fkDE. diIspar C.ilitated al P by C. lonalt santibodi i 9 t3inst tions to the study of membrane proteins”. Methods Enzymol. -kDa surface antigen”; Parasitol Res, May 1, , pp. ty. 125:27-35 (1986). European Search Report issued on Mar. 21, 2016, regarding EP 12 Maggio, E.T., “Intravail: highly effective intranasal delivery of 165 052.7. peptide and protein drugs'. Expert Opin. Drug Deliv. 3(4):529-39 (2006). * cited by examiner U.S. Patent Sep. 20, 2016 Sheet 1 of 15 US 9,446,134 B2 Background Information Figure 1 U.S. Patent Sep. 20, 2016 Sheet 2 of 15 US 9,446,134 B2 insulin pH 6.5 1200 1OOO -- Control s 8OO -- 0.062% A 0.125% A 600 - x - O.25.0% A 5. 400 -k- OO62 B -o-O.125% B 200 --O.250% B O O 1 2 6 9 13 16 2O Days 37C Figure 2 U.S. Patent Sep. 20, 2016 Sheet 3 of 15 US 9,446,134 B2 insulin pH 7.4 -0- Control -- 0.062% A c -- 0.125% A s -3%a O.250% A wd -- 0.062% B e -O-O.125% B -- 0.250% B Days 37C Figure 3 U.S. Patent Sep. 20, 2016 Sheet 4 of 15 US 9,446,134 B2 hCGh pH 6.5 Intravail 0.125% 10ul sample -0- Control --Intravail 7 10 13 16 20 Days hGH pH 6.5 intravail 0.124% 5ul Sample 1 5O 1 OO -0- Control 5O -- intravail O O 1 2 3 7 10 13 16 20 Figure 4 U.S. Patent Sep. 20, 2016 Sheet 5 Of 15 US 9,446,134 B2 Comparison of Time Dependent Effect of Aggregation of Peptide T (DAPTA) Stored at 4 Degrees for Prolong Period of Time (Lot 036299) s -0-6 h 14 degree s w -- 1 week s -A-2 weeks - orio 3 weeks w -- 4 weeks -O-2 months -10 -9 Peptide T (DAPTA) LogM Figure 5 U.S. Patent Sep. 20, 2016 Sheet 6 of 15 US 9,446,134 B2 DAPTA Formulation (0.5 mg/ml). Inhibition of HIV-1 (ADA) Infection of Macrophages: Various Treatments for Stability A3+ DAPTA/ not TFE Tx, aged 14d A3+ DAPTAWTFE Tx, aged 14d DAPTA/TFE Tx, aged i4d B3+ DAPTA/ no TFE Tx, aged 14d B3 + DAPTA/TFE, aged 14d DAPTA aged 14d DAPTA aged 7d Virus only 25 50 75 1OO 1.25 Reverse Transcriptase Activity Percent of Virus Only Control by 0.1nM DAPTA Figure 6 U.S. Patent Sep. 20, 2016 Sheet 7 Of 15 US 9,446,134 B2 insulin pH 7.6 1 O OO s (d t w c o - es s 1. 11 14 20 27 39 45 54 60 67 75 82 88 Days at 37C, 150 RPM -- Control -A-0.1% dodecyl maltoside (less than 10% B anomer) --X -- 0.2% dodecyl maltoside (less than 10% B anomer) - - -X -- 0.1% dodecyl maltoside (greater than 99% B anomer) -o-0.2% dodecyl maltoside (greater than 99% 8 anomer) Figure 7 U.S. Patent Sep. 20, 2016 Sheet 8 of 15 US 9,446,134 B2 Ostabolin C, pH 3.5 40 deg. C, 150 RPM 120 OO 8 O 60 40 20 -20 O.O 2.0 4.0 6.0 8.0 0.0 2.0 14.0 Figure 8 U.S. Patent Sep. 20, 2016 Sheet 9 Of 15 US 9,446,134 B2 Ostabolin C, pH 5.0 40 deg. C, 150 RPM 1000 8 O O 0.0 2.0 4.0 6.0 8.0 10.0 2.0 14.0 Figure 9 U.S. Patent Sep. 20, 2016 Sheet 10 of 15 US 9,446,134 B2 PTH 1-34, pH 3.0, 40 deg. C 0. 0 O 800 6 0 0 - 400 200 rer Figure 10 U.S. Patent Sep. 20, 2016 Sheet 11 of 15 US 9.446,134 B2 PTH 1-34, pH 5.0, 40 deg. C 200 - Figure 11 U.S. Patent Sep. 20, 2016 Sheet 12 of 15 US 9.446,134 B2 1200 PTH 1-34, pH 5.0 at 37 deg. C 1000 800 600 400 200 -200 Day Figure 12 U.S. Patent Sep. 20, 2016 Sheet 13 of 15 US 9,446,134 B2 800 700 600 500 400 300 200 100 |--|--|-- |--|--|-- |-|--|-- 0.00twE.
Load more

Recommended publications
  • BAFF-Neutralizing Interaction of Belimumab Related to Its Therapeutic Efficacy for Treating Systemic Lupus Erythematosus
    ARTICLE DOI: 10.1038/s41467-018-03620-2 OPEN BAFF-neutralizing interaction of belimumab related to its therapeutic efficacy for treating systemic lupus erythematosus Woori Shin1, Hyun Tae Lee1, Heejin Lim1, Sang Hyung Lee1, Ji Young Son1, Jee Un Lee1, Ki-Young Yoo1, Seong Eon Ryu2, Jaejun Rhie1, Ju Yeon Lee1 & Yong-Seok Heo1 1234567890():,; BAFF, a member of the TNF superfamily, has been recognized as a good target for auto- immune diseases. Belimumab, an anti-BAFF monoclonal antibody, was approved by the FDA for use in treating systemic lupus erythematosus. However, the molecular basis of BAFF neutralization by belimumab remains unclear. Here our crystal structure of the BAFF–belimumab Fab complex shows the precise epitope and the BAFF-neutralizing mechanism of belimumab, and demonstrates that the therapeutic activity of belimumab involves not only antagonizing the BAFF–receptor interaction, but also disrupting the for- mation of the more active BAFF 60-mer to favor the induction of the less active BAFF trimer through interaction with the flap region of BAFF. In addition, the belimumab HCDR3 loop mimics the DxL(V/L) motif of BAFF receptors, thereby binding to BAFF in a similar manner as endogenous BAFF receptors. Our data thus provides insights for the design of new drugs targeting BAFF for the treatment of autoimmune diseases. 1 Department of Chemistry, Konkuk University, 120 Neungdong-ro, Gwangjin-gu, Seoul 05029, Republic of Korea. 2 Department of Bio Engineering, Hanyang University, 222 Wangsimni-ro, Seongdong-gu, Seoul 04763, Republic of Korea. These authors contributed equally: Woori Shin, Hyun Tae Lee, Heejin Lim, Sang Hyung Lee.
    [Show full text]
  • Old and New Challenges in Uveitis Associated with Behçet's Disease
    Journal of Clinical Medicine Review Old and New Challenges in Uveitis Associated with Behçet’s Disease Julie Gueudry 1,* , Mathilde Leclercq 2, David Saadoun 3,4,5 and Bahram Bodaghi 6 1 Department of Ophthalmology, Hôpital Charles Nicolle, F-76000 Rouen, France 2 Department of Internal Medicine, Hôpital Charles Nicolle, F-76000 Rouen, France; [email protected] 3 Department of Internal Medicine and Clinical Immunology, AP-HP, Centre National de Références Maladies Autoimmunes et Systémiques Rares et Maladies Autoinflammatoires Rares, Groupe Hospitalier Pitié-Salpêtrière, F-75013 Paris, France; [email protected] 4 Sorbonne Universités, UPMC Univ Paris 06, INSERM, UMR S 959, Immunology-Immunopathology-Immunotherapy (I3), F-75005 Paris, France 5 Biotherapy (CIC-BTi), Hôpital Pitié-Salpêtrière, AP-HP, F-75651 Paris, France 6 Department of Ophthalmology, IHU FOReSIGHT, Sorbonne-AP-HP, Groupe Hospitalier Pitié-Salpêtrière, F-75013 Paris, France; [email protected] * Correspondence: [email protected]; Tel.: +33-2-32-88-80-57 Abstract: Behçet’s disease (BD) is a systemic vasculitis disease of unknown origin occurring in young people, which can be venous, arterial or both, classically occlusive. Ocular involvement is particularly frequent and severe; vascular occlusion secondary to retinal vasculitis may lead to rapid and severe loss of vision. Biologics have transformed the management of intraocular inflammation. However, the diagnosis of BD is still a major challenge. In the absence of a reliable biological marker, diagnosis is based on clinical diagnostic criteria and may be delayed after the appearance of the onset sign. However, therapeutic management of BD needs to be introduced early in order to control inflammation, to preserve visual function and to limit irreversible structural damage.
    [Show full text]
  • Fig. L COMPOSITIONS and METHODS to INHIBIT STEM CELL and PROGENITOR CELL BINDING to LYMPHOID TISSUE and for REGENERATING GERMINAL CENTERS in LYMPHATIC TISSUES
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date Χ 23 February 2012 (23.02.2012) WO 2U12/U24519ft ft A2 (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, A61K 31/00 (2006.01) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, PCT/US201 1/048297 KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, (22) International Filing Date: ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, 18 August 201 1 (18.08.201 1) NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (25) Filing Language: English TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (26) Publication Language: English ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/374,943 18 August 2010 (18.08.2010) US kind of regional protection available): ARIPO (BW, GH, 61/441,485 10 February 201 1 (10.02.201 1) US GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, 61/449,372 4 March 201 1 (04.03.201 1) US ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (72) Inventor; and EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, ΓΓ, LT, LU, (71) Applicant : DEISHER, Theresa [US/US]; 1420 Fifth LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, Avenue, Seattle, WA 98101 (US).
    [Show full text]
  • Ocrevus (Ocrelizumab) Policy Number: C11250-A
    Prior Authorization Criteria Ocrevus (ocrelizumab) Policy Number: C11250-A CRITERIA EFFECTIVE DATES: ORIGINAL EFFECTIVE DATE LAST REVIEWED DATE NEXT REVIEW DUE BY OR BEFORE 8/1/2017 2/17/2021 4/26/2022 LAST P&T J CODE TYPE OF CRITERIA APPROVAL/VERSION J2350-injection,ocrelizumab, Q2 2021 RxPA 1mg 20200428C11250-A PRODUCTS AFFECTED: Ocrevus (ocrelizumab) DRUG CLASS: Multiple Sclerosis Agents - Monoclonal Antibodies ROUTE OF ADMINISTRATION: Intravenous PLACE OF SERVICE: Specialty Pharmacy or Buy and Bill The recommendation is that medications in this policy will be for pharmacy benefit coverage and the IV infusion products administered in a place of service that is a non-hospital facility-based location (i.e., home infusion provider, provider’s office, free-standing ambulatory infusion center) AVAILABLE DOSAGE FORMS: Ocrevus SOLN 300MG/10ML FDA-APPROVED USES: Indicated for the treatment of: • Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing- remitting disease, and active secondary progressive disease, in adults • Primary progressive MS, in adults COMPENDIAL APPROVED OFF-LABELED USES: None COVERAGE CRITERIA: INITIAL AUTHORIZATION DIAGNOSIS: Multiple Sclerosis REQUIRED MEDICAL INFORMATION: A. RELAPSING FORMS OF MULTIPLE SCLEROSIS: 1. Documentation of a definitive diagnosis of a relapsing form of multiple sclerosis as defined by the McDonald criteria (see Appendix), including: Relapsing- remitting multiple sclerosis [RRMS], secondary-progressive multiple sclerosis [SPMS] with relapses, and progressive- relapsing multiple sclerosis [PRMS] or First clinical episode with MRI features consistent with multiple sclerosis Molina Healthcare, Inc. confidential and proprietary © 2021 This document contains confidential and proprietary information of Molina Healthcare and cannot be reproduced, distributed, or printed without written permission from Molina Healthcare.
    [Show full text]
  • Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies
    Predictive QSAR tools to aid in early process development of monoclonal antibodies John Micael Andreas Karlberg Published work submitted to Newcastle University for the degree of Doctor of Philosophy in the School of Engineering November 2019 Abstract Monoclonal antibodies (mAbs) have become one of the fastest growing markets for diagnostic and therapeutic treatments over the last 30 years with a global sales revenue around $89 billion reported in 2017. A popular framework widely used in pharmaceutical industries for designing manufacturing processes for mAbs is Quality by Design (QbD) due to providing a structured and systematic approach in investigation and screening process parameters that might influence the product quality. However, due to the large number of product quality attributes (CQAs) and process parameters that exist in an mAb process platform, extensive investigation is needed to characterise their impact on the product quality which makes the process development costly and time consuming. There is thus an urgent need for methods and tools that can be used for early risk-based selection of critical product properties and process factors to reduce the number of potential factors that have to be investigated, thereby aiding in speeding up the process development and reduce costs. In this study, a framework for predictive model development based on Quantitative Structure- Activity Relationship (QSAR) modelling was developed to link structural features and properties of mAbs to Hydrophobic Interaction Chromatography (HIC) retention times and expressed mAb yield from HEK cells. Model development was based on a structured approach for incremental model refinement and evaluation that aided in increasing model performance until becoming acceptable in accordance to the OECD guidelines for QSAR models.
    [Show full text]
  • Exploring the Association Between Monoclonal Antibodies and Depression and Suicidal Ideation and Behavior: a Vigibase Study
    Drug Safety https://doi.org/10.1007/s40264-018-00789-9 ORIGINAL RESEARCH ARTICLE Exploring the Association between Monoclonal Antibodies and Depression and Suicidal Ideation and Behavior: A VigiBase Study Lotte A. Minnema1,2 · Thijs J. Giezen2,3 · Patrick C. Souverein1 · Toine C. G. Egberts1,4 · Hubert G. M. Leufkens1 · Helga Gardarsdottir1,4,5 © The Author(s) 2019 Abstract Introduction Several monoclonal antibodies (mAbs) have been linked to neuropsychiatric adverse efects in patients, includ- ing depression and suicidal ideation and behavior. Objective The aim of this study was to quantify and characterize spontaneously reported adverse drug reactions (ADRs) of depression and suicidal ideation and behavior related to mAb users, and to explore a possible association with their mecha- nism of action. Methods We included mAb ADRs that were reported in VigiBase, and identifed those related to depression and suicidal ideation and behavior. Reporting odds ratios (RORs) were estimated for each mAb (bevacizumab as the reference) and according to their infuence on the immune system (not directly targeting [reference], stimulating, or suppressing). Those suppressing the immune system were further divided into their intended indication (auto-immune diseases, cancer). Results Overall, 2,924,319 ADRs for 44 mAbs were included; 9455 ADRs were related to depression and 1770 were related to suicidal ideation and behavior. The association was strongest for natalizumab and belimumab, both for depression (ROR 5.7, 95% confdence interval [CI] 5.0–6.4; and ROR 5.1, 95% CI 4.2–6.2) and suicidal ideation and behavior (ROR 12.0, 95% CI 7.9–18.3; and ROR 20.2, 95% CI 12.4–33.0).
    [Show full text]
  • Malignant B Lymphocyte Survival in Vivo CD22 Ligand Binding Regulates Normal
    The Journal of Immunology CD22 Ligand Binding Regulates Normal and Malignant B Lymphocyte Survival In Vivo1 Karen M. Haas, Suman Sen, Isaac G. Sanford, Ann S. Miller, Jonathan C. Poe, and Thomas F. Tedder2 The CD22 extracellular domain regulates B lymphocyte function by interacting with ␣2,6-linked sialic acid-bearing ligands. To understand how CD22 ligand interactions affect B cell function in vivo, mouse anti-mouse CD22 mAbs were generated that inhibit CD22 ligand binding to varying degrees. Remarkably, mAbs which blocked CD22 ligand binding accelerated mature B cell turnover by 2- to 4-fold in blood, spleen, and lymph nodes. CD22 ligand-blocking mAbs also inhibited the survival of adoptively transferred normal (73–88%) and malignant (90%) B cells in vivo. Moreover, mAbs that bound CD22 ligand binding domains induced significant CD22 internalization, depleted marginal zone B cells (82–99%), and reduced mature recirculating B cell numbers by 75–85%. The CD22 mAb effects were independent of complement and FcRs, and the CD22 mAbs had minimal effects in CD22AA mice that express mutated CD22 that is not capable of ligand binding. These data demonstrate that inhibition of CD22 ligand binding can disrupt normal and malignant B cell survival in vivo and suggest a novel mechanism of action for therapeutics targeting CD22 ligand binding domains. The Journal of Immunology, 2006, 177: 3063–3073. D22 is a B cell-specific glycoprotein of the Ig superfam- cell surface CD22, IgM, and MHC class II expression on mature B ily expressed on the surface of maturing B cells coinci- cells, whereas normal BCR signaling and Ca2ϩ mobilization are dent with IgD expression (1, 2).
    [Show full text]
  • Therapeutic and Prophylactic Use of Oral, Low-Dose Ifns in Species of Veterinary Interest: Back to the Future
    veterinary sciences Review Therapeutic and Prophylactic Use of Oral, Low-Dose IFNs in Species of Veterinary Interest: Back to the Future Sara Frazzini 1 , Federica Riva 2,* and Massimo Amadori 3 1 Gastroenterology and Endoscopy Unit, Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico, 20122 Milan, Italy; [email protected] 2 Dipartimento di Medicina Veterinaria, Università degli Studi di Milano, 26900 Lodi, Italy 3 Rete Nazionale di Immunologia Veterinaria, 25125 Brescia, Italy; [email protected] * Correspondence: [email protected]; Tel.: +39-0250334519 Abstract: Cytokines are important molecules that orchestrate the immune response. Given their role, cytokines have been explored as drugs in immunotherapy in the fight against different pathological conditions such as bacterial and viral infections, autoimmune diseases, transplantation and cancer. One of the problems related to their administration consists in the definition of the correct dose to avoid severe side effects. In the 70s and 80s different studies demonstrated the efficacy of cytokines in veterinary medicine, but soon the investigations were abandoned in favor of more profitable drugs such as antibiotics. Recently, the World Health Organization has deeply discouraged the use of antibiotics in order to reduce the spread of multi-drug resistant microorganisms. In this respect, the use of cytokines to prevent or ameliorate infectious diseases has been highlighted, and several studies show the potential of their use in therapy and prophylaxis also in the veterinary field. In this review we aim to review the principles of cytokine treatments, mainly IFNs, and to update the experiences encountered in animals. Keywords: veterinary immunotherapy; cytokines; IFN; low dose treatment; oral treatment Citation: Frazzini, S.; Riva, F.; Amadori, M.
    [Show full text]
  • Interleukins in Therapeutics
    67 ISSN: 2347 - 7881 Review Article Interleukins in Therapeutics Anjan Khadka Department of Pharmacology, AFMC, Pune, India [email protected] ABSTRACT Interleukins are a subset of a larger group of cellular messenger molecules called cytokines, which are modulators of cellular behaviour. On the basis of their respective cytokine profiles, responses to chemokines, and interactions with other cells, these T-cell subsets can promote different types of inflammatory responses. During the development of allergic disease, effector TH2 cells produce IL-4, IL- 5, IL-9, and IL-32. IL-25, IL- 31, and IL-33 contributes to TH2 responses and inflammation. These cytokines have roles in production of allergen-specific IgE, eosinophilia, and mucus. ILs have role in therapeutics as well as diagnosis and prognosis as biomarker in various conditions. Therapeutic targeting of the IL considered to be rational treatment strategy and promising biologic therapy. Keywords: Interleukins, cytokines, Interleukin Inhibitors, Advances INTRODUCTION meaning ‘hormones’. It was Stanley Cohen in Interleukins are group of cytokines that were 1974 who for the first time introduced the term first seen to be expressed by leucocytes and ‘‘cytokine’’. It includes lymphokines, they interact between cells of the immune monokines, interleukins, and colony stimulating systems. It is termed by Dr. Vern Paetkau factors (CSFs), interferons (IFNs), tumor (University of Victoria) in1979.Interleukins (IL) necrosis factor (TNF) and chemokines. The are able to promote cell growth, differentiation, majority of interleukins are synthesized by and functional activation. The question of how helper CD4 T lymphocytes as well as through diverse cell types communicate with each monocytes, macrophages, and endothelial cells.
    [Show full text]
  • Challenges and Approaches for the Development of Safer Immunomodulatory Biologics
    REVIEWS Challenges and approaches for the development of safer immunomodulatory biologics Jean G. Sathish1*, Swaminathan Sethu1*, Marie-Christine Bielsky2, Lolke de Haan3, Neil S. French1, Karthik Govindappa1, James Green4, Christopher E. M. Griffiths5, Stephen Holgate6, David Jones2, Ian Kimber7, Jonathan Moggs8, Dean J. Naisbitt1, Munir Pirmohamed1, Gabriele Reichmann9, Jennifer Sims10, Meena Subramanyam11, Marque D. Todd12, Jan Willem Van Der Laan13, Richard J. Weaver14 and B. Kevin Park1 Abstract | Immunomodulatory biologics, which render their therapeutic effects by modulating or harnessing immune responses, have proven their therapeutic utility in several complex conditions including cancer and autoimmune diseases. However, unwanted adverse reactions — including serious infections, malignancy, cytokine release syndrome, anaphylaxis and hypersensitivity as well as immunogenicity — pose a challenge to the development of new (and safer) immunomodulatory biologics. In this article, we assess the safety issues associated with immunomodulatory biologics and discuss the current approaches for predicting and mitigating adverse reactions associated with their use. We also outline how these approaches can inform the development of safer immunomodulatory biologics. Immunomodulatory Biologics currently represent more than 30% of licensed The high specificity of the interactions of immu- biologics pharmaceutical products and have expanded the thera- nomodulatory biologics with their relevant immune Biotechnology-derived peutic options available
    [Show full text]
  • Afelimomab (Rinn) Ic Medicines Under the Following Names: Adonis V
    2248 Supplementary Drugs and Other Substances Adiphenine Hydrochloride (USAN, rINNM) Adrenalone Hydrochloride (pINNM) ⊗ Uses. The use of aesculus has been reviewed;1,2 although there is some evidence suggesting benefit in chronic venous insuffi- Adiphénine, Chlorhydrate d’; Adiphenini Hydrochloridum; Adrénalone, Chlorhydrate d’; Adrenaloni Hydrochloridum; ciency, more rigorous studies are needed.2 Cloridrato de Adifenina; Hidrocloruro de adifenina; NSC- Adrenalonu chlorowodorek; Hidrocloruro de adrenalona. 1. Sirtori CR. Aescin: pharmacology, pharmacokinetics and thera- 129224; Spasmolytine. Адреналона Гидрохлорид peutic profile. Pharmacol Res 2001; 44: 183–93. Адифенина Гидрохлорид C H NO ,HCl = 217.6. 2. Pittler MH, Ernst E. Horse chestnut seed extract for chronic ve- 9 11 3 nous insufficiency. Available in The Cochrane Database of Sys- C20H25NO2,HCl = 347.9. CAS — 62-13-5. tematic Reviews; Issue 1. Chichester: John Wiley; 2006 (ac- CAS — 50-42-0. ATC — A01AD06; B02BC05. cessed 31/03/06). ATC Vet — QA01AD06; QB02BC05. Profile Preparations Adiphenine and adiphenine hydrochloride have been used as Profile Proprietary Preparations (details are given in Part 3) antispasmodics. Adrenalone hydrochloride is used as a local haemostatic and va- Arg.: Grafic Retard; Herbaccion Venotonico; Nadem; Venastat; Venostasin; soconstrictor. It has also been used with adrenaline in eye drops Austria: Aesculaforce; Provenen; Reparil; Venosin; Venostasin; Belg.: Preparations for glaucoma. Reparil; Veinofytol; Venoplant; Braz.: Phytovein; Reparil; Varilise;
    [Show full text]
  • Simulect® (Basiliximab)
    UnitedHealthcare® Value & Balance Exchange Medical Benefit Drug Policy Simulect® (Basiliximab) Policy Number: IEXD0219.02 Effective Date: July 1, 2021 Instructions for Use Table of Contents Page Related Policies Applicable States ........................................................................... 1 None Coverage Rationale ....................................................................... 1 Applicable Codes .......................................................................... 1 Background.................................................................................... 2 Clinical Evidence ........................................................................... 2 U.S. Food and Drug Administration ............................................. 2 References ..................................................................................... 2 Policy History/Revision Information ............................................. 2 Instructions for Use ....................................................................... 3 Applicable States This Medical Benefit Drug Policy only applies to the states of Arizona, Maryland, North Carolina, Oklahoma, Tennessee, Virginia, and Washington. Coverage Rationale Simulect is proven and medically necessary for the treatment of prophylaxis of acute organ rejection when all of the following criteria are met: Patient has received a kidney transplant; and Physician provided documentation that patient’s prophylaxis therapy includes cyclosporine modified and corticosteroids; and Simulect
    [Show full text]